Form 4: Oncology Institute CFO Acquires Shares and Warrants in Private Placement

Robert Ross Carter, CFO of Oncology Institute, purchased shares and warrants in a private placement transaction.

Summary

• Robert Ross Carter, the Chief Financial Officer of Oncology Institute, Inc. [TOI], reported a transaction on March 26, 2025.
• Carter acquired 9,056 shares of common stock at $1.0417 per share and 4,528 common warrants at $0.1250 per warrant.
• These securities were purchased through a private placement transaction directly from the company, as per a Securities Purchase Agreement dated March 24, 2025.
• Each private placement unit consisted of two shares of common stock and one common warrant, priced at $2.2084 per unit.
• Following the transaction, Carter directly owns 39,407 shares of common stock and 4,528 common warrants.
• The warrants are exercisable immediately and expire on March 26, 2030, with an exercise price of $1.198.
• Carter is restricted from exercising the warrants to the extent that it would result in him beneficially owning more than 4.99% of the company's outstanding common stock.

Sentiment

Score: 6

Explanation: Neutral sentiment. It's a standard disclosure of insider activity. The CFO's purchase could be seen as positive, but it's a relatively small transaction.

Positives

• The CFO's investment in the company could be seen as a sign of confidence in Oncology Institute's future prospects.

Risks

• The warrant exercise restriction could limit Carter's potential gains if the stock price increases significantly.
• Private placements can sometimes dilute existing shareholders' equity.

Future Outlook

The document does not contain specific forward-looking statements beyond the warrant's expiration date and exercise limitations.

Industry Context

This transaction is a routine disclosure of insider trading activity. It doesn't provide specific insights into the broader oncology industry but reflects the CFO's investment decision in his own company.

Comparison to Industry Standards

• Insider transactions are common across publicly traded companies, including those in the healthcare and oncology sectors.
• Comparing the size and nature of this transaction to similar insider purchases at companies like Exact Sciences (EXAS) or Guardant Health (GH) would provide context, but that data is not available in this document.
• The warrant structure is fairly standard, similar to those used in private placements by other small-cap companies.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment, as it signals confidence from a key executive.
• The private placement may slightly dilute existing shareholders.

Key Dates

Keywords

Oncology Institute, TOI, Robert Ross Carter, CFO, private placement, common stock, common warrant, Securities Purchase Agreement, beneficial ownership, Form 4